DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast

Not Applicable

Recruiting

• Conditions: Breast Neoplasms
• Interventions: Procedure: Modified radical mastectomy; Procedure: Expanded Mckissock surgery

• Registration Number: NCT04052893
• Lead Sponsor: Shengjing Hospital

Brief Summary

Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal carcinoma in situ (DCIS) in or around the invasive carcinoma. Compared with DCIS negative for extensive intraductal component, DCIS positive for extensive intraductal component is not sensitive to radiotherapy. Mckissock surgery was applied in breast-conserving surgery for breast cancer in 2016. Jianyi Li and the team members (Shengjing Hospital of China Medical University, Shenyang, China) applied this technique in breast-conserving surgery with preservation of the nipple-areola complex. This surgical technique is suitable for low-grade malignant tumors and has better prognosis than radical mastectomy. The purpose of this study is to investigate postoperative disease-free survival and quality of life after modified radical mastectomy versus expanded Mckissock surgery for extensive intraductal carcinoma of the breast. Results from this study will indicate the efficacy of expanded Mckissock surgery in the treatment of extensive intraducatal carcinoma of the breast.

Detailed Description

Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal carcinoma in situ (DCIS) in or around the invasive carcinoma. Studies have shown that patients with DCIS positive for extensive intraductal component have more residual tumors than patients with DCIS negative for extensive intraductal component. There are still many subclinical tumors in the residual mammary gland after removal of the main invasive tumor foci. This provides the condition for tumor recurrence after breast-conserving surgery, and the risk of tumor recurrence in DCIS positive for extensive intraductal component is 2.52 times that in DCIS negative for extensive intraductal component. Compared with DCIS negative for extensive intraductal component, DCIS positive for extensive intraductal component is not sensitive to radiotherapy.

Mckissock surgery is originated from a breast reduction surgery developed by American doctors in 1970, which can remove glands to the maximum extent. This technique was applied to breast-conserving surgery in 2016, which initiated the application of this operation in malignant tumors. Jianyi Li and the team members (Shengjing Hospital of China Medical University, Shenyang, China) first applied expanded Mckissock surgery in breast-conserving surgery with the nipple-areola complex preserved. This surgical technique is suitable for low-grade malignant tumors. This surgical technique has been performed in 30 patients and results showed that the expanded Mckissock surgery has better prognosis than radical mastectomy. Therefore, this prospective cohort study will compare the postoperative disease-free survival and quality of life between modified radical mastectomy and expanded Mckissock surgery.

Study Timeline

• Study First Submitted: 2019-08-06
• Study First Submitted QC: 2019-08-08
• Study First Posted: 2019-08-12
• Study Start: 2019-10-01
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-06
• Last Update Posted: 2022-02-08
• Primary Completion: 2025-09-01
• Study Completion: 2026-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

• Patients with extensive intraductal carcinoma confirmed by hollow needle biopsy;
• the lesion not involving the nipple as confirmed by enhanced MR imaging of the breast;
• Bra cup size: B or higher;
• postmenopausal patients;
• provision of written informed consent.

Read More

Exclusion Criteria

• The cutting edge of nipple-areola complex tested positive for extensive intraductal carcinoma twice;
• preoperative nipple hemorrhage;
• bilateral breast cancer;
• inflammatory breast cancer;
• distant metastasis;
• other cancers or those who receive chest radiotherapy.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Modified radical mastectomy	100 patients will be assigned into a control group.
Study group	Expanded Mckissock surgery	100 patients will be assigned into a study group.

Primary Outcome Measures

Name	Time	Method
Disease-free survival.	5 years	Disease-free survival refers to the time from surgical resection of breast cancer to clinically confirmed local recurrence, distant metastasis, second primary tumor diagnosis, or patient death.

Secondary Outcome Measures

Name	Time	Method
European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) scale	5 years	The QLQ-BR23 scale will evaluate the quality of life. The QLQ-BR23 scale consists of 23 items with a full score of 92. Higher score indicates poor quality of life.
Breast symmetry	5 years	The symmetry of reconstructed breast will be evaluated using Harris score. The Harris score was described by Harris et al. (Int J Radiat Oncol Biol Phys 1979; 5: 257- 261.) It will be divided into four levels: excellent, good, fair, and poor.
Medical cost	During hospitalization, an average of 2 weeks	Including medical insurance and commercial insurance reimbursement.

Trial Locations

Locations (3)

Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute; 🇨🇳 Shengyang, Liaoning, China

General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group; 🇨🇳 Benxi, Liaoning, China

Shengjing Hospital of China Medical University; 🇨🇳 Shenyang, Liaoning, China